MondegarAI
Redmile Group, LLC

Q4 2024 · 13F-HR

Redmile Group, LLCholdings as filed

Filed 2025-02-14 · accession 0001104659-25-014154

$1.43B
Reported value
62
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
80706P103SRRKSCHOLAR ROCK HLDG CORP$196.6M13.7%4,549,881CommonSOLE
501147102KRYSKRYSTAL BIOTECH INC$118.0M8.22%753,175CommonSOLE
67080M103NRIXNURIX THERAPEUTICS INC$79.0M5.50%4,192,627CommonSOLE
98985Y108ZYMEZYMEWORKS INC$70.9M4.94%4,840,463CommonSOLE
03152W109AM6AMICUS THERAPEUTICS INC$66.5M4.63%7,054,890CommonSOLE
76029N106REPLREPLIMUNE GROUP INC$59.4M4.14%4,905,527CommonSOLE
45257U108IMNMIMMUNOME INC$51.3M3.57%4,828,026CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$50.7M3.53%4,593,629CommonSOLE
G5509L101LIVNLIVANOVA PLC$48.3M3.37%1,043,539CommonSOLE
501575104KYMRKYMERA THERAPEUTICS INC$44.3M3.09%1,100,432CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$38.1M2.66%2,895,478CommonSOLE
07373V105BEAMBEAM THERAPEUTICS INC$37.9M2.64%1,528,567CommonSOLE
75901B107RGNXREGENXBIO INC$37.1M2.58%4,794,780CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$34.4M2.39%1,235,209CommonSOLE
G1110E107BHVNBIOHAVEN LTD$33.8M2.35%904,496CommonSOLE
03589W102ANNXANNEXON INC$32.3M2.25%6,300,644CommonSOLE
H0036K147ADCTADC THERAPEUTICS SA$31.2M2.17%15,666,731CommonSOLE
64135M105NGNENEUROGENE INC$30.2M2.10%1,319,763CommonSOLE
101137107BSXBOSTON SCIENTIFIC CORP$27.9M1.95%312,683CommonSOLE
19240Q201COGTCOGENT BIOSCIENCES INC$27.7M1.93%3,554,836CommonSOLE
00091E109ABSIABSCI CORPORATION$21.6M1.51%8,253,316CommonSOLE
31189P102FATEFATE THERAPEUTICS INC$21.2M1.48%12,872,946CommonSOLE
4495851081K0IGM BIOSCIENCES INC$18.0M1.26%2,952,131CommonSOLE
282559103ETNBGBP89BIO INC$16.9M1.18%2,167,176CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$16.5M1.15%2,399,317CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$15.9M1.11%619,300CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC NEW$15.6M1.08%615,775CommonSOLE
G31249108ESTAESTABLISHMENT LABS HLDGS INC$14.7M1.03%320,149CommonSOLE
45258J102IMVTIMMUNOVANT INC$14.2M0.99%571,824CommonSOLE
15678C102CBLLCERIBELL INC$11.3M0.79%435,239CommonSOLE
863667101SYKSTRYKER CORPORATION$11.0M0.77%30,676CommonSOLE
75382E109RAPT THERAPEUTICS INC$10.2M0.71%6,475,317CommonSOLE
09075V102BNTXBIONTECH SE$9.5M0.66%83,471CommonSOLE
46120E602ISRGINTUITIVE SURGICAL INC$8.8M0.62%16,943CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$8.7M0.61%552,506CommonSOLE
67080N101NUVBNUVATION BIO INC$8.1M0.56%3,031,009CommonSOLE
039697107ARDXARDELYX INC$8.0M0.56%1,576,259CommonSOLE
687604108ORKAORUKA THERAPEUTICS INC$8.0M0.56%411,728CommonSOLE
92539P101VERVE THERAPEUTICS INC$7.4M0.52%1,318,164CommonSOLE
82024L103STTKSHATTUCK LABS INC$6.7M0.47%5,539,724CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS IN$6.7M0.46%1,196,910CommonSOLE
00166B105ALXOALX ONCOLOGY HLDGS INC$6.2M0.43%3,689,611CommonSOLE
70975L107PENPENUMBRA INC$6.1M0.43%25,743CommonSOLE
74168J101PRMEPRIME MEDICINE INC$6.1M0.42%2,074,350CommonSOLE
046513206ATRAATARA BIOTHERAPEUTICS INC$5.9M0.41%441,701CommonSOLE
23282W605CYTKCYTOKINETICS INC$4.4M0.30%92,598CommonSOLE
85916J409STXSSTEREOTAXIS INC$4.1M0.29%1,799,465CommonSOLE
01671P100ALLKGUSDALLAKOS INC$3.6M0.25%3,015,097CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$3.1M0.22%346,278CommonSOLE
H00263105ACIUAC IMMUNE SA$2.8M0.19%1,034,299CommonSOLE
760273102RPTXREPARE THERAPEUTICS INC$2.5M0.17%1,916,089CommonSOLE
45784P101PODDINSULET CORP$2.5M0.17%9,559CommonSOLE
83422E204SLDBSOLID BIOSCIENCES INC$2.5M0.17%615,246CommonSOLE
10170A100BOLDBOUNDLESS BIO INC$2.1M0.15%740,204CommonSOLE
N515171054PKBLAVA THERAPEUTICS NV$2.0M0.14%2,074,372CommonSOLE
00449L102698ACHILLES THERAPEUTICS PLC$1.8M0.13%1,608,089CommonSOLE
98422E103XERSXERIS BIOPHARMA HOLDINGS INC$1.5M0.11%451,099CommonSOLE
00534A102IVVDINVIVYD INC$1.3M0.09%3,012,254CommonSOLE
019818103ALLOVIR INC$801,3470.06%1,907,969CommonSOLE
00653A107ADAPYADAPTIMMUNE THERAPEUTICS PLC$385,4970.03%715,607CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$271,9500.02%124,178CommonSOLE
43906K209HOOKHOOKIPA PHARMA INC$213,8160.01%106,376CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.